Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Asthma is estimated to affect as many as 300 million people worldwide and its incidence and prevalence are rapidly increasing throughout the world, especially in children and within developing countries. Recently, there has been a growing interest in the use of potentially beneficial bacteria for allergic diseases. This study is aimed at exploring the therapeutic effects of long-term treatment with two different beneficial bacterial strains (Bifidobacterium breve M-16 V and Lactobacillus rhamnosus NutRes1) and a glucocorticoid (budesonide), as a reference treatment, on inflammatory response in a murine model for chronic allergic asthma. METHODS: To mimic the chronic disease in asthmatic patients, we used the murine ovalbumin-induced asthma model combined with prolonged allergen exposure. Airway function; pulmonary airway inflammation; airway remodelling, mRNA expression of pattern recognition receptors, Th-specific cytokines and transcription factors in lung tissue; mast cell degranulation; in vitro T cell activation; and expression of Foxp3 in blood Th cells were examined. RESULTS: Lactobacillus rhamnosus reduced lung resistance to a similar extent as budesonide treatment in chronically asthmatic mice. Pulmonary airway inflammation, mast cell degranulation, T cell activation and airway remodelling were suppressed by all treatments. Beneficial bacteria and budesonide differentially modulated the expression of toll-like receptors (TLRs), nod-like receptors (NLRs), cytokines and T cell transcription factors. Bifidobacterium breve induced regulatory T cell responses in the airways by increasing Il10 and Foxp3 transcription in lung tissue as well as systemic by augmenting the mean fluorescence intensity of Foxp3 in blood CD4+ T cells. CONCLUSION: These findings show that Bifidobacterium breve M-16 V and Lactobacillus rhamnosus NutRes1 have strong anti-inflammatory properties that are comparable to budesonide and therefore may be beneficial in the treatment of chronic asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity
Clarke, T. B., Davis, K. M., Lysenko, E. S., Zhou, A. Y., Yu, Y., & Weiser, J. N. (2010) · Nature Medicine · doi:10.1038/nm.2087 · Cited by 1,154 · cited 2×
“Single nucleotide polymorphisms in Nod1 gene were positively associated with susceptibility towards asthma in farming children and this PRR was reported to be necessary for neutrophil function in mice [25,33-35].”
BackgroundSevere asthma: Advances in current management and future therapy
Barnes, P. J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.006 · Cited by 174 · cited 1×
“Glucocorticoids (GCs) are by far the most effective treatments for asthma [12].”
BackgroundProbiotics for the prevention of respiratory tract infections: a systematic review
Vouloumanou, E. K., Makris, G. C., Karageorgopoulos, D. E., & Falagas, M. E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.11.005 · Cited by 131 · cited 1×
“The potential role of beneficial bacteria, such as probiotics, as modulators of the intestinal microbiota and mucosal immune responses has been extensively investigated and discussed in the last few years [17-19].”
Background
Cited by
The Gut–Lung Axis in Respiratory Disease
Marsland, B. J., Trompette, A., & Gollwitzer, E. S. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201503-133aw · Cited by 630
The influence of the microbiome on respiratory health
Wypych, T. P., Wickramasinghe, L. C., & Marsland, B. J. (2019) · Nature Immunology · doi:10.1038/s41590-019-0451-9 · Cited by 611
Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis
Westfall, S., Lomis, N., Kahouli, I., Dia, S. Y., Singh, S. P., & Prakash, S. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2550-9 · Cited by 541
Diet, Microbiota and Gut-Lung Connection
Anand, S., & Mande, S. S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02147 · Cited by 409
Mechanistic insight into the function of the microbiome in lung diseases
Ubags, N. D. J., & Marsland, B. J. (2017) · European Respiratory Journal · doi:10.1183/13993003.02467-2016 · Cited by 109
Metadata
- Authors
- Sagar, S., Morgan, M. E., Chen, S., Vos, A. P., Garssen, J., van Bergenhenegouwen, J., Boon, L., Georgiou, N. A., Kraneveld, A. D., & Folkerts, G.
- Venue
- Respiratory Research
- Published
- 2014
- Volume
- 15
- Issue
- 1
- Pages
- 46
- ISSN
- 1465-9921 (ISSN-L)
- OpenAlex
- W2124804278
- Cited by
- 115
- References
- 3
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma. https://app.cochat.ai/papers/10.1186/1465-9921-15-46
- The paper
- Sagar, S., Morgan, M. E., Chen, S., Vos, A. P., Garssen, J., van Bergenhenegouwen, J., Boon, L., Georgiou, N. A., Kraneveld, A. D., & Folkerts, G. (2014). Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma. Respiratory Research. https://doi.org/10.1186/1465-9921-15-46
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.